ÂÜŔňÂŇÂ×

Dr. Erhardt recently joined Oligomerix as Chief Medical Officer and will be responsible for helping transition Oligomerix’s lead compound through IND and into clinical development. Most recently, he was Senior Vice President, Head of Clinical Development & Operations at Pfizer responsible for design, conduct and reporting of Pfizer’s global Clinical Development portfolio. He oversaw Pfizer’s Clinical, Clinical Sciences, Clinical Project Management and Pfizer’s Internal Phase I Clinical Research units in New Haven and Brussels, Belgium. In this role, Dr. Erhardt was responsible for all Pfizer Clinical Development functions for a portfolio of 350 clinical studies across the Cardiovascular, Metabolic, Neuroscience, Vaccines, Immunology & Inflammation and Rare Disease therapeutic areas and managing a budget of $250M. Dr. Erhardt also spent several years at FDA as Medical Reviewer in the Infectious Diseases group and has excellent understanding of FDA processes. He is a seasoned pharmaceutical executive with broad global experience in medical, clinical operations and development. Dr. Erhardt is a board certified, sub-specialty physician (Pediatric Infectious Diseases) with experience within the pharmaceutical industry across numerous therapeutic areas encompassing all phases of drug development as well as all aspects of medical product support. His background is complimented by significant organizational design and leadership experience. Dr. Erhardt received his B.A. in Electrical Engineering from Brown University and his M.D. from the State University of New York Health Science Center at Syracuse. He completed his Pediatric Residency and Chief Residency at North Shore University Hospital/Cornell University Medical College and his Fellowship in Infectious Diseases at the Children’s National Medical Center.